A Randomised, Double-blinded, Placebo-controlled Trial Using Cardiovascular Magnetic Resonance (CMR) Scanning to Assess Remodelling and Regression of Fibrosis in Cardiomyopathy with Eplerenone

Trial Profile

A Randomised, Double-blinded, Placebo-controlled Trial Using Cardiovascular Magnetic Resonance (CMR) Scanning to Assess Remodelling and Regression of Fibrosis in Cardiomyopathy with Eplerenone

Completed
Phase of Trial: Phase IV

Latest Information Update: 17 Oct 2017

At a glance

  • Drugs Eplerenone (Primary)
  • Indications Cardiomyopathies
  • Focus Therapeutic Use
  • Acronyms Heston
  • Most Recent Events

    • 11 Sep 2013 Status changed from active, no longer recruiting to completed as reported by ISRCTN: Current Controlled Trials.
    • 06 Aug 2012 Status changed from recruiting to active, no longer recruiting as reported by United Kingdom Clinical Research Network record.
    • 05 Mar 2012 United Kingdom Clinical Research Network reports accrual to date changed from 27% to 28%.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top